# Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

> **NCT01445821** · PHASE3 · TERMINATED · sponsor: **Northwestern University** · enrollment: 44 (actual)

## Conditions studied

- Scleroderma, Systemic

## Interventions

- **BIOLOGICAL:** Peripheral Blood Stem Cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **DRUG:** rATG
- **DRUG:** Methylprednisolone
- **DRUG:** Filgrastim
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT01445821
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09-15
- **Primary completion:** 2017-01-05
- **Final completion:** 2019-10-10
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Developed a better regimen: DIAD. Cast. 2018 NCT03593902
- **Last updated:** 2020-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01445821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01445821, "Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01445821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*